Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy

Clicks: 340
ID: 267789
2000
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #6 of 8 articles by views in HIV medicine

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
We conclude that improved immune function in immunodeficient patients treated with HAART may restore pathogen-specific immune responses and cause inflammation in tissues infected by those pathogens.
Reference Key
ma2000hivimmune Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors French MA;Lenzo N;John M;Mallal SA;McKinnon EJ;James IR;Price P;Flexman JP;Tay-Kearney ML;;
Journal HIV medicine
Year 2000
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/11737333
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't adult female male Retrospective Studies antiretroviral therapy cd4 lymphocyte count hiv infections / immunology* highly active* hiv infections / drug therapy* immunocompromised host* aids-related opportunistic infections / immunology* pmid:11737333 doi:10.1046/j.1468-1293.2000.00012.x m a french n lenzo m l tay-kearney immune system / drug effects*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.